1. Home
  2. JFR vs MGTX Comparison

JFR vs MGTX Comparison

Compare JFR & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Floating Rate Income Fund

JFR

Nuveen Floating Rate Income Fund

HOLD

Current Price

$7.52

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$14.80

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFR
MGTX
Founded
2004
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
JFR
MGTX
Price
$7.52
$14.80
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$24.57
AVG Volume (30 Days)
563.4K
543.8K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
11.31%
N/A
EPS Growth
N/A
33.02
EPS
N/A
1.30
Revenue
N/A
$81,391,000.00
Revenue This Year
N/A
$141.38
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$11.03
Revenue Growth
N/A
144.57
52 Week Low
$7.16
$6.62
52 Week High
$8.45
$15.35

Technical Indicators

Market Signals
Indicator
JFR
MGTX
Relative Strength Index (RSI) 32.46 68.43
Support Level $7.44 $7.04
Resistance Level $7.60 $15.35
Average True Range (ATR) 0.06 0.73
MACD -0.03 0.19
Stochastic Oscillator 3.03 94.20

Price Performance

Historical Comparison
JFR
MGTX

About JFR Nuveen Floating Rate Income Fund

Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: